Infliximab (Remicade, Flixabi, Inflectra, Remsima and Zessly): Use of live vaccines in infants exposed in utero or during breastfeeding

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
  • Remicade
  • Flixabi
  • Inflectra
  • Remsima
  • Zessly
Active substance
infliximab
Therapeutic area (MeSH)
  • Spondylitis, Ankylosing
  • Arthritis, Rheumatoid
  • Psoriasis
  • Crohn Disease
  • Arthritis, Psoriatic
  • Colitis, Ulcerative
Procedure number
EMEA/H/C/000240/IB/233
Regulatory outcome
Variation
DHPC type
New contraindication
Human ATC code
L04AB02
Dissemination date
07/03/2022

How useful was this page?

Add your rating
Average
1 rating